Oxybutynin Dosage

Medically reviewed by Drugs.com. Last updated on Oct 3, 2023.

Usual Adult Dose for Urinary Incontinence

Immediate Release Tablets/Syrup:
Initial dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day

Extended Release Tablets:
Initial dose: 5 to 10 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increments weekly as tolerated
Maximum dose: 30 mg/day

Transdermal Gel 10%:
The contents of one sachet or one actuation of the metered-dose pump applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Uses:

• Immediate release tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)
• Extended-release tablets: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
• Gel: For overactive bladder with urge urinary incontinence, urgency and frequency

Usual Adult Dose for Urinary Frequency

Immediate Release Tablets/Syrup:
Initial dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day

Extended Release Tablets:
Initial dose: 5 to 10 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increments weekly as tolerated
Maximum dose: 30 mg/day

Transdermal Gel 10%:
The contents of one sachet or one actuation of the metered-dose pump applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Uses:

• Immediate release tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)
• Extended-release tablets: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
• Gel: For overactive bladder with urge urinary incontinence, urgency and frequency

Usual Adult Dose for Neurogenic Bladder

Immediate Release Tablets/Syrup:
Initial dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day

Extended Release Tablets:
Initial dose: 5 to 10 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increments weekly as tolerated
Maximum dose: 30 mg/day

Transdermal Gel 10%:
The contents of one sachet or one actuation of the metered-dose pump applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Uses:

• Immediate release tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)
• Extended-release tablets: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
• Gel: For overactive bladder with urge urinary incontinence, urgency and frequency

Usual Geriatric Dose for Urinary Incontinence

Immediate Release Tablets/Syrup:
Initial dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day
NOTE: Initial dose for the frail elderly is 2.5 mg orally 2 to 3 times a day

Extended Release Tablets:
Initial dose: 5 to 10 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increment

Transdermal Gel 10%:
The contents of one sachet or one actuation of the metered-dose pump applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Uses:

• Immediate release tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)
• Extended-release tablets: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Usual Geriatric Dose for Urinary Frequency

Immediate Release Tablets/Syrup:
Initial dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day
NOTE: Initial dose for the frail elderly is 2.5 mg orally 2 to 3 times a day

Extended Release Tablets:
Initial dose: 5 to 10 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increment

Transdermal Gel 10%:
The contents of one sachet or one actuation of the metered-dose pump applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Uses:

• Immediate release tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)
• Extended-release tablets: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Usual Geriatric Dose for Neurogenic Bladder

Immediate Release Tablets/Syrup:
Initial dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day
NOTE: Initial dose for the frail elderly is 2.5 mg orally 2 to 3 times a day

Extended Release Tablets:
Initial dose: 5 to 10 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increment

Transdermal Gel 10%:
The contents of one sachet or one actuation of the metered-dose pump applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Uses:

• Immediate release tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)
• Extended-release tablets: For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Usual Pediatric Dose for Urinary Incontinence

Immediate Release Tablets:
5 years and older:
Initial dose: 5 mg orally 2 times a day
Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets/Syrup:
6 years and older:
Initial dose: 5 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increments weekly as tolerated
Maximum dose: 30 mg/day

Uses:

• Immediate Release Tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
• Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Pediatric Dose for Urinary Frequency

Immediate Release Tablets:
5 years and older:
Initial dose: 5 mg orally 2 times a day
Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets/Syrup:
6 years and older:
Initial dose: 5 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increments weekly as tolerated
Maximum dose: 30 mg/day

Uses:

• Immediate Release Tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
• Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Pediatric Dose for Neurogenic Bladder

Immediate Release Tablets:
5 years and older:
Initial dose: 5 mg orally 2 times a day
Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets/Syrup:
6 years and older:
Initial dose: 5 mg orally once a day at the same time each day
Titration: Adjust in 5 mg increments weekly as tolerated
Maximum dose: 30 mg/day

Uses:

• Immediate Release Tablets/Syrup: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
• Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Renal Dose Adjustments

Caution recommended.

Liver Dose Adjustments

Caution recommended.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients
• Unstable cardiovascular status in acute hemorrhage
• Urinary retention
• Myasthenia gravis
• Toxic megacolon complicating ulcerative colitis
• Severe colitis
• GI retention and other severe decreased GI motility conditions
• Uncontrolled narrow-angle glaucoma

Tablet/Syrup/Solution: Safety and efficacy have not been established in patients younger than 5 years.
Extended release: Safety and efficacy have not been established in patients younger than 6 years.
Patch/Gel: Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Swallow tablet whole, with water.
• Swallow extended release tablets whole; do not chew, crush, or divide.
• Extended release tablets may be taken with or without food, at the same time each day.
• The tablet/syrup/solution formulations should be taken with food or milk to decrease GI distress.
• In case of a missed dose, the next dose should be taken at the regular time.
• The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet.
• A new application site should be selected with each new patch to avoid reapplication to the same site within 7 days.

Monitoring:

• Monitor for anticholinergic effects in first few months of beginning therapy or increasing dosage.

Patient advice:

• Heat prostration (fever and heat stroke due to decreased sweating) can occur when this drug is administered in the presence of high environmental temperature.
• Patients should be advised to exercise caution because this drug can cause drowsiness (somnolence) or blurred vision.
• Alcohol may enhance the drowsiness caused by this drug.
• In case of a missed dose, the patient should wait and take the next dose at the regular time.
• The extended-release formulation is contained within a nondeformable material that is eliminated from the body and may appear in the stool.
• This drug is associated with anticholinergic central nervous system (CNS) effects, including hallucinations, agitation, confusion, and somnolence.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer